Does Reimbursement Affect Physicians’ Decision Making? Examples from the Use of Recombinent Erythropoietin

  • June M. McKoy
  • Cara C. Tigue
  • Charles L. Bennett
Part of the Cancer Treatment and Research book series (CTAR, volume 140)


National Comprehensive Cancer Network Darbepoetin Alfa Recombinant Human Erythropoietin Anemic Cancer Patient Oncologic Drug Advisory Committee 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pronzato P. Cancer-related anaemia management in the 21st century. Cancer Treat Rev 32 Suppl 2:S1–S3, 2006.PubMedCrossRefGoogle Scholar
  2. 2.
    Bohlius J, Weingart O, Trelle S, et al. Cancer-related anemia and recombinant human erythropoietin–an updated overview. Nat Clin Pract Oncol 3:152–164, 2006.PubMedCrossRefGoogle Scholar
  3. 3.
    Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460, 2003.PubMedCrossRefGoogle Scholar
  4. 4.
    Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960–5972, 2005.PubMedCrossRefGoogle Scholar
  5. 5.
    DAHANCA 10 Trial. The Cancer Letter 33, February 23, 2007.Google Scholar
  6. 6.
    Centers for Medicare and Medicaid Services (CMS). Available at Accessed March 14, 2007.Google Scholar
  7. 7.
    Elliot C: Where ethics comes from and what to do about it. Hastings Cent Rep 22:28–35, 1992.Google Scholar
  8. 8.
    Ackerman T, Strong C: Casebook of Medical Ethics. New York, Oxford University Press, 1989.Google Scholar
  9. 9.
    President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Making Health Care Decisions, Vol 1. Washington, DC, Government Printing Office, 1982.Google Scholar
  10. 10.
    Callahan S. The role of emotion in ethical decisionmaking. Hastings Cent Rep 18:9–14, 1988.PubMedGoogle Scholar
  11. 11.
    Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083–4107, 2002.PubMedCrossRefGoogle Scholar
  12. 12.
    Cancer- and treatment-related anemia v.2.2006.Clinical Practice Guidelines in Oncology. gls/PDF/anemia.pdf (accessed October 6, 2006), National Comprehensive Cancer Network, 2006.Google Scholar
  13. 13.
    Repetto L, Moeremans K, Annemans L. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. Cancer Treat Rev 32 Suppl 2:S5–S9, 2006.CrossRefGoogle Scholar
  14. 14.
    Beauchamp T, Childress J. The Principles of Biomedical Ethics (ed 4th ed). New York, Oxford University Press, 1992.Google Scholar
  15. 15.
    Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 8:149–156, 2005.Google Scholar
  16. 16.
    MacLaren R, Sullivan PW. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. Value Health 8:105–116, 2005.PubMedCrossRefGoogle Scholar
  17. 17.
    Smith DH, Adams JR, Johnston SR, et al. A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 13:1590–1597, 2002.PubMedCrossRefGoogle Scholar
  18. 18.
    Laird J: Erythropoietin: can we afford to use it? Can we afford not to? Transfus Med 16:204–205, 2006.PubMedCrossRefGoogle Scholar
  19. 19.
    Armour BS, Pitts MM, Maclean R, et al. The effect of explicit financial incentives on physician behavior. Arch Intern Med 161:1261–1266, 2001.PubMedCrossRefGoogle Scholar
  20. 20.
    Miller TE, Sage WM. Disclosing physician financial incentives. JAMA 281:1424–30, 1999.PubMedCrossRefGoogle Scholar
  21. 21.
    Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Williston Park) 16:17–24, 2002.Google Scholar
  22. 22.
    NHS in England. Available at TheNhs/History/Default.cmsx. Accessed March 6, 2007.Google Scholar
  23. 23.
    GAO: Medicare. Physician Incentive Payments by Prepaid Health Plans Could Lower Quality of Care. Report to the Chairman, Subcommittee on Health, Committee on Ways and Means. U.S. House of Representatives, December 1988.Google Scholar
  24. 24.
    Brody H. Transparency: Informed consent in primary care. Hastings Cent Rep 19, 1989.Google Scholar
  25. 25.
    Mehlman M. Fiduciary contracting: limitations on bargaining between patients and health care providers. Univ Pittsbg Law Rev 51:365–417, 1990.Google Scholar
  26. 26.
    Birgegard G, Bokemeyer C. New guidelines on anaemia management in patients with cancer: How do these affect clinical practice? Oncology 69 Suppl 2:17–21, 2005.Google Scholar
  27. 27.
    Engert A. Recombinant human erythropoietin in oncology: current status and further developments. Ann Oncol 16:1584–1595, 2005.PubMedCrossRefGoogle Scholar
  28. 28.
    Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260, 2003.PubMedCrossRefGoogle Scholar
  29. 29.
    Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714, 2006.PubMedGoogle Scholar
  30. 30.
    Randal J. FDA panel scrutinizes safety of anti-anemia drugs. J Natl Cancer Inst 96:1061, 2004.PubMedCrossRefGoogle Scholar
  31. 31.
    Goldberg P. FDA’s ODAC to review EPO Agents in May; SEC probes Amgen delay in study disclosure. The Cancer Letter 33:1, 7–11, 2007.Google Scholar
  32. 32.
    Aranesp (darbepoetin alfa) Safety. Oncologic Drugs Advisory Committee, 2004.Google Scholar
  33. 33.
    Luksenburg H. Evolving safety issues assocaited with erythropoietin products, 2004.Google Scholar
  34. 34.
    R. Niesvizky AS, M. Wang, D. Weber, C. Chen, M. A. Dimopoulos, Z. Yu, Z. Yu, R. Delap, J. Zeldis, R. D. Knight. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin, 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol, 7506.Google Scholar
  35. 35.
    Strupp C, Germing U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16:1–6, 2002.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • June M. McKoy
  • Cara C. Tigue
  • Charles L. Bennett

There are no affiliations available

Personalised recommendations